anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ethyl 2-(4-fluoro-7-methylsulfonyloxy-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetate
Trial phase: Phase 2
SMILES: CCOC(=O)Cc1c2n(c3c(F)cccc13)CC(OS(C)(=O)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 126
Group description: Participants receive MK-1029 30 mg tablets QD for 12 weeks
Eligibility criteria:
Inclusion Criteria:

not pregnant or breastfeeding, and not planning to become pregnant during the study
history of symptoms of persistent asthma for at least one year

current use of acceptable asthma treatments and willingness to taper or discontinue these treatments; acceptable asthma treatments:

use of inhaled SABAs (e.g., albuterol/salbutamol) only "as-needed" with no use of asthma controller medications; OR
use of stable doses of low- or medium-dose inhaled corticosteroids (ICS), alone, or in combination with either a long-acting beta-agonist (LABA) or other asthma controller medications (including leukotriene receptor antagonists) and can tolerate tapering or discontinuation
no history of smoking OR no smoking within <1 year with a smoking history of ≤10 pack-years
ability to maintain a constant day/night, awake/sleep cycle
agreement to not change habitual consumption of beverages or food containing caffeine throughout the study
Body Mass Index (BMI) of 15 to 40 kg/m^2

Exclusion Criteria:

myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within past ≤3 months
hospitalization within past ≤4 weeks
major surgical procedure within past ≤4 weeks
participation in a clinical study involving an investigational drug within past ≤4 weeks
current regular use or recent (within past ≤5 years) past abuse of alcohol (>14 drinks/week) or illicit drugs
donation of a unit of blood within past ≤2 weeks or intention to donate a unit of blood during the study
evidence of another clinically significant, active pulmonary disorder such as chronic obstructive pulmonary disease (COPD)
emergency room treatment for asthma within past ≤4 weeks or hospitalization for asthma within past ≤8 weeks
respiratory tract infection requiring antibiotic treatment within past ≤8 weeks
evidence of active, clinically significant sinus disease within past ≤1 week
history of a clinically significant psychiatric disorder, other than stable depression, within past ≤12 weeks
history of HIV
hypersensitivity or intolerance to inhaled beta-agonists, leukotriene antagonists, leukotriene synthesis inhibitors, or any of their ingredients, including lactose and galactose
clinically unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems
current cancer or history (within past ≤5 years) of cancer (except for successfully treated basal and squamous cell carcinomas of the skin); if cancer-free for >5 years, study participation may be allowed
evidence of uncontrolled hypertension
Intervention: Ethyl 2-(4-fluoro-7-methylsulfonyloxy-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetate
Trial phase: Phase 2
SMILES: CCOC(=O)Cc1c2n(c3c(F)cccc13)CC(OS(C)(=O)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 135
Group description: Participants receive MK-1029 two 30 mg tablets QD for 12 weeks
Eligibility criteria:
Inclusion Criteria:

not pregnant or breastfeeding, and not planning to become pregnant during the study
history of symptoms of persistent asthma for at least one year

current use of acceptable asthma treatments and willingness to taper or discontinue these treatments; acceptable asthma treatments:

use of inhaled SABAs (e.g., albuterol/salbutamol) only "as-needed" with no use of asthma controller medications; OR
use of stable doses of low- or medium-dose inhaled corticosteroids (ICS), alone, or in combination with either a long-acting beta-agonist (LABA) or other asthma controller medications (including leukotriene receptor antagonists) and can tolerate tapering or discontinuation
no history of smoking OR no smoking within <1 year with a smoking history of ≤10 pack-years
ability to maintain a constant day/night, awake/sleep cycle
agreement to not change habitual consumption of beverages or food containing caffeine throughout the study
Body Mass Index (BMI) of 15 to 40 kg/m^2

Exclusion Criteria:

myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within past ≤3 months
hospitalization within past ≤4 weeks
major surgical procedure within past ≤4 weeks
participation in a clinical study involving an investigational drug within past ≤4 weeks
current regular use or recent (within past ≤5 years) past abuse of alcohol (>14 drinks/week) or illicit drugs
donation of a unit of blood within past ≤2 weeks or intention to donate a unit of blood during the study
evidence of another clinically significant, active pulmonary disorder such as chronic obstructive pulmonary disease (COPD)
emergency room treatment for asthma within past ≤4 weeks or hospitalization for asthma within past ≤8 weeks
respiratory tract infection requiring antibiotic treatment within past ≤8 weeks
evidence of active, clinically significant sinus disease within past ≤1 week
history of a clinically significant psychiatric disorder, other than stable depression, within past ≤12 weeks
history of HIV
hypersensitivity or intolerance to inhaled beta-agonists, leukotriene antagonists, leukotriene synthesis inhibitors, or any of their ingredients, including lactose and galactose
clinically unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems
current cancer or history (within past ≤5 years) of cancer (except for successfully treated basal and squamous cell carcinomas of the skin); if cancer-free for >5 years, study participation may be allowed
evidence of uncontrolled hypertension
Intervention: Ethyl 2-(4-fluoro-7-methylsulfonyloxy-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetate
Trial phase: Phase 2
SMILES: CCOC(=O)Cc1c2n(c3c(F)cccc13)CC(OS(C)(=O)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: Participants receive MK-1029 150 mg tablets QD for 12 weeks
Eligibility criteria:
Inclusion Criteria:

not pregnant or breastfeeding, and not planning to become pregnant during the study
history of symptoms of persistent asthma for at least one year

current use of acceptable asthma treatments and willingness to taper or discontinue these treatments; acceptable asthma treatments:

use of inhaled SABAs (e.g., albuterol/salbutamol) only "as-needed" with no use of asthma controller medications; OR
use of stable doses of low- or medium-dose inhaled corticosteroids (ICS), alone, or in combination with either a long-acting beta-agonist (LABA) or other asthma controller medications (including leukotriene receptor antagonists) and can tolerate tapering or discontinuation
no history of smoking OR no smoking within <1 year with a smoking history of ≤10 pack-years
ability to maintain a constant day/night, awake/sleep cycle
agreement to not change habitual consumption of beverages or food containing caffeine throughout the study
Body Mass Index (BMI) of 15 to 40 kg/m^2

Exclusion Criteria:

myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within past ≤3 months
hospitalization within past ≤4 weeks
major surgical procedure within past ≤4 weeks
participation in a clinical study involving an investigational drug within past ≤4 weeks
current regular use or recent (within past ≤5 years) past abuse of alcohol (>14 drinks/week) or illicit drugs
donation of a unit of blood within past ≤2 weeks or intention to donate a unit of blood during the study
evidence of another clinically significant, active pulmonary disorder such as chronic obstructive pulmonary disease (COPD)
emergency room treatment for asthma within past ≤4 weeks or hospitalization for asthma within past ≤8 weeks
respiratory tract infection requiring antibiotic treatment within past ≤8 weeks
evidence of active, clinically significant sinus disease within past ≤1 week
history of a clinically significant psychiatric disorder, other than stable depression, within past ≤12 weeks
history of HIV
hypersensitivity or intolerance to inhaled beta-agonists, leukotriene antagonists, leukotriene synthesis inhibitors, or any of their ingredients, including lactose and galactose
clinically unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems
current cancer or history (within past ≤5 years) of cancer (except for successfully treated basal and squamous cell carcinomas of the skin); if cancer-free for >5 years, study participation may be allowed
evidence of uncontrolled hypertension
Intervention: Montelukast
Trial phase: Phase 2
ATC code: R03DC03 | R03DC53
SMILES: CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Participants receive Montelukast 10 mg tablets QD for 12 weeks
Eligibility criteria:
Inclusion Criteria:

not pregnant or breastfeeding, and not planning to become pregnant during the study
history of symptoms of persistent asthma for at least one year

current use of acceptable asthma treatments and willingness to taper or discontinue these treatments; acceptable asthma treatments:

use of inhaled SABAs (e.g., albuterol/salbutamol) only "as-needed" with no use of asthma controller medications; OR
use of stable doses of low- or medium-dose inhaled corticosteroids (ICS), alone, or in combination with either a long-acting beta-agonist (LABA) or other asthma controller medications (including leukotriene receptor antagonists) and can tolerate tapering or discontinuation
no history of smoking OR no smoking within <1 year with a smoking history of ≤10 pack-years
ability to maintain a constant day/night, awake/sleep cycle
agreement to not change habitual consumption of beverages or food containing caffeine throughout the study
Body Mass Index (BMI) of 15 to 40 kg/m^2

Exclusion Criteria:

myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within past ≤3 months
hospitalization within past ≤4 weeks
major surgical procedure within past ≤4 weeks
participation in a clinical study involving an investigational drug within past ≤4 weeks
current regular use or recent (within past ≤5 years) past abuse of alcohol (>14 drinks/week) or illicit drugs
donation of a unit of blood within past ≤2 weeks or intention to donate a unit of blood during the study
evidence of another clinically significant, active pulmonary disorder such as chronic obstructive pulmonary disease (COPD)
emergency room treatment for asthma within past ≤4 weeks or hospitalization for asthma within past ≤8 weeks
respiratory tract infection requiring antibiotic treatment within past ≤8 weeks
evidence of active, clinically significant sinus disease within past ≤1 week
history of a clinically significant psychiatric disorder, other than stable depression, within past ≤12 weeks
history of HIV
hypersensitivity or intolerance to inhaled beta-agonists, leukotriene antagonists, leukotriene synthesis inhibitors, or any of their ingredients, including lactose and galactose
clinically unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems
current cancer or history (within past ≤5 years) of cancer (except for successfully treated basal and squamous cell carcinomas of the skin); if cancer-free for >5 years, study participation may be allowed
evidence of uncontrolled hypertension
Intervention: TERIPARATIDE
Trial phase: Not Applicable
ATC code: H05AA02
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: teriparatide 20 mcg sq for 3 months

Teriparatide: 20 mcg subq daily for 3 months
Eligibility criteria:
Inclusion Criteria:

Post-menopausal women aged 50-80 years
T score < -2.5 at lumbar spine, total hip or femoral neck on dual x-ray absorptiometry (DXA) OR T score < -1.5 with a personal or family history of fracture

Exclusion Criteria:

Previous use of bisphosphonates or Teriparatide; current estrogen therapy; any other osteoporosis therapy in the past 6 months
Metabolic bone disease other than osteoporosis
Body mass index (BMI) < 18
Weight > 325 lbs
Current smoking or current alcohol use that exceeds 3 units of alcohol daily
Use of medications known to affect bone metabolism
Renal disease, history of kidney stones or hypercalciuria
Hypo- or hyperparathyroidism; hypo- or hypercalcemia
Serum vitamin D level < 20 ng/dL
Refusal to adjust their dietary calcium to <750mg (i.e. two servings per day of calcium rich food)
History of bone marrow or organ transplant
History of malignancy or radiation to the bone
History of esophageal stricture, dysmotility or severe reflux disease
Gastrointestinal malabsorption
Use of digoxin
Need for chronic anticoagulation therapy such as Coumadin, heparin or low molecular weight heparin or inability to discontinue anti-platelet medication
Bleeding diathesis; hemoglobin ≤ 12.5 g/dL (American Red Cross cut-off to donate blood)
International normalized ratio (INR) pro time > 1.1 or activated partial thromboplastin time (APT) T ratio > 1.2
Platelets < 150K/cu mm
Cellulitis at site of iliac crest
History of allergy to medications used in bone biopsy (demeclocycline, lidocaine)
Inability to understand and provide informed consent.
Intervention: ALENDRONIC ACID
Trial phase: Not Applicable
ATC code: M05BA04 | M05BB03 | M05BB05 | M05BB06
SMILES: NCCCC(O)(P(=O)(O)O)P(=O)(O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: 70 mg po weekly for 3 months

Alendronate: 70 mg weekly for 3 months
Eligibility criteria:
Inclusion Criteria:

Post-menopausal women aged 50-80 years
T score < -2.5 at lumbar spine, total hip or femoral neck on dual x-ray absorptiometry (DXA) OR T score < -1.5 with a personal or family history of fracture

Exclusion Criteria:

Previous use of bisphosphonates or Teriparatide; current estrogen therapy; any other osteoporosis therapy in the past 6 months
Metabolic bone disease other than osteoporosis
Body mass index (BMI) < 18
Weight > 325 lbs
Current smoking or current alcohol use that exceeds 3 units of alcohol daily
Use of medications known to affect bone metabolism
Renal disease, history of kidney stones or hypercalciuria
Hypo- or hyperparathyroidism; hypo- or hypercalcemia
Serum vitamin D level < 20 ng/dL
Refusal to adjust their dietary calcium to <750mg (i.e. two servings per day of calcium rich food)
History of bone marrow or organ transplant
History of malignancy or radiation to the bone
History of esophageal stricture, dysmotility or severe reflux disease
Gastrointestinal malabsorption
Use of digoxin
Need for chronic anticoagulation therapy such as Coumadin, heparin or low molecular weight heparin or inability to discontinue anti-platelet medication
Bleeding diathesis; hemoglobin ≤ 12.5 g/dL (American Red Cross cut-off to donate blood)
International normalized ratio (INR) pro time > 1.1 or activated partial thromboplastin time (APT) T ratio > 1.2
Platelets < 150K/cu mm
Cellulitis at site of iliac crest
History of allergy to medications used in bone biopsy (demeclocycline, lidocaine)
Inability to understand and provide informed consent.
Intervention: Nicotine
Trial phase: Phase 4
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.

Nicotrol Inhaler: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper Placebo Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
Eligibility criteria:
Inclusion Criteria:

smoking at least 5 cigarettes per day for the preceding 7 days
previous attempt to quit smoking during pregnancy by self report
13-26 weeks gestation
at least 16 years of age
able to speak English or Spanish
intent to carry pregnancy to term
stable residence

Exclusion Criteria:

current drug or alcohol abuse or dependence (other than methadone maintenance)
twins or other multiple gestation
unstable psychiatric disorder
unstable medical problems (e.g., pre-eclampsia, threatened abortion, hyperemesis gravidarum)
known congenital abnormality
Intervention: PROPYLENE GLYCOL
Trial phase: Phase 3
SMILES: CC(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar

doses: 1 drop in each eye, quarter in day

Systane: Instill 1 drop in each eye four times a day, for 60 days
Eligibility criteria:
Inclusion Criteria:

Mild to moderate dry eye patients based on the Report of International Dry Eye Workshop (DEWS)
OSDI score between 12 and 45
Provided informed consent

Exclusion Criteria:

Patients with one blind eye
Visual acuity of 20/100 or worst in any eye
Patients with any active ocular disease that would interfere with study interpretation
Patients in treatment with any medication that could interfere with the study, contraindication of any medication used in the protocol
Patients with history of hypersensitivity or contraindication for any drug used in the study
Contact lens users
Pregnant patients, at risk of pregnancy or breastfeeding
Patients without birth control treatment
Patients who had participated in any clinical trial in the last 90 days
Legal or mentally disabled patients who could not give informed consent
Patients who do not provide informed consent
Intervention: Nepafenac
Trial phase: Phase 2
ATC code: S01BC10
SMILES: NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 75
Group description: Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension

Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye

Maintenance therapy: 1 drop 3 times a day for 30 days

Nevanac: Pre-medication (before surgery) and maintenance treatment.
Eligibility criteria:
Inclusion Criteria:

Patients older than 18 years who require cataract surgery
Both genders
Provide informed consent
Normal Laboratory results

Exclusion Criteria:

Patients with visual acuity of 20/40 or less in the contralateral eye of the surgery
Patients with any trans-surgical complication
Patients with a cataract >NC4, C4 or P4 classified with the system LOCS
Patients with any active corneal pathology
Patients under any steroidal treatment (topic, systemic or inhaled)14 days prior surgery or NSAIDs 7 days before the surgery (except low-dose aspirin)
Patients with IOP <5 or >21 mmHg
Patients that have ocular pain, cellularity or flare at the moment of selection
Patients with ocular exfoliation, trauma or any inflammatory disease
Patients with diabetic retinopathy that need treatment or uncontrolled diabetes mellitus
Patients who are planning cataract surgery of the contralateral eye 14 days after surgery of the study eye
Patients with history of hypersensitivity or contraindication for any drug used in the study
Patients under anticoagulant treatment
Contact lens users
Pregnant patients, at risk of pregnancy or breastfeeding
Patients without birth control treatment
Patients with any active toxicomania (alcoholism, cigarette, cannabis or others)
Patients who had participated in any clinical trial in the last 90 days
Legal or mentally disabled patients who could not give informed consent
Patients who cannot comply with all study requirements
Intervention: POTASSIUM NITRATE
Trial phase: Not Applicable
SMILES: O=[N+]([O-])[O-].[K+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 56
Group description: Participants brushed with a fluoride free toothpaste (0 ppmF) containing only 5% w/w KNO3.
Eligibility criteria:
Inclusion Criteria:

General and Oral Health: Good general health with (in the opinion of the investigator) no clinically OST and OHT examinations.

Oral Requirements:

An intact maxillary dental arch suitable for the retention of the palatal appliance and an intact mandibular dental arch. Subjects may have fixed bridges replacing missing teeth.
A gum base stimulated whole saliva flow rate ≥ 0.8 g/min and an unstimulated whole saliva flow rate ≥ 0.2 g/min.
Contraception: Women of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.

Exclusion Criteria:

Oral Health:

Current active caries or periodontal disease that may compromise the study or the health of the subjects.
Lesions of the oral cavity that could interfere with the study evaluations, including severe gingivitis, grossly carious lesions, periodontitis and other severe periodontal disease.
Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.

Clinical Study/Experimental Medication:

Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit
Previous participation in this study
Substance abuse: Recent history (within the last year) of alcohol or other substance abuse.
Pregnancy: Women who are pregnant or who are intending to become pregnant over the duration of the study
Breast-feeding: Women who are breast-feeding
Intervention: Doxycycline
Trial phase: Phase 3
ATC code: A01AB22 | J01AA02 | J01AA20
SMILES: [H][C@@]12C(=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]3([H])[C@H]1O)C(=O)c1c(O)cccc1[C@@H]2C
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 82
Group description: Subjects who were randomization into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received Doxycycline 100 mg oral capsules, twice daily for 10 days. After 10 days subsequent treatment can requested by the subjects
Eligibility criteria:
Inclusion Criteria:

Premenopausal women, aged 18-51 years
Expressed desire for compliance-independent contraception
No current pregnancy or anticipated desire for childbearing within 3 years of study enrollment and Implanon insertion
Agreement to participate in all study related procedures and evaluations as documented by a signed informed consent

Exclusion Criteria:

Current or prior use of Implanon
Current long-term use of Doxycycline for other indications
Known structural uterine abnormalities such as polyp, submucosal leiomyoma
Prior permanent sterilization or endometrial ablation
Pregnancy or desire for childbearing within 3 years
Contraindications to or intolerance of etonogestrel
Allergy to or intolerance of Doxycycline
Inability or unwillingness to complete study related procedures and evaluations